Cargando…

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line

SIMPLE SUMMARY: Lapatinib is a tyrosine kinase inhibitor widely used as a treatment for a Human Epidermal growth factor Receptor 2 (HER2) (+) breast cancer patients. However, when resistance is acquired through continued exposure, and it is associated with a poor prognosis for patients. In this stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hye Jin, Shin, Seungho, Kang, Jinho, Han, Ki-Cheol, Kim, Yeul Hong, Bae, Jeoung-Won, Park, Kyong Hwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564044/ https://www.ncbi.nlm.nih.gov/pubmed/32942617 http://dx.doi.org/10.3390/cancers12092630

Ejemplares similares

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
por: Park, Kang-Seo, et al.
Publicado: (2018)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
por: Christenson, Jessica L., et al.
Publicado: (2015)

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
por: Saleem, Azeem, et al.
Publicado: (2015)

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
por: Bai, Zhiqing, et al.
Publicado: (2022)

Development and Characterization of PLGA Nanoparticles Containing 17-DMAG, an Hsp90 Inhibitor
por: Cruz, Kercia P., et al.
Publicado: (2021)

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2011)

Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
por: Saleem, Azeem, et al.
Publicado: (2017)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma
por: Singh, Shivendra, et al.
Publicado: (2020)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
por: Bao, Shengnan, et al.
Publicado: (2020)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

The Hsp90 Inhibitor 17-DMAG Attenuates Hyperglycemia-Enhanced Hemorrhagic Transformation in Experimental Stroke
por: Zhang, Jiaming, et al.
Publicado: (2021)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
por: Brain, E, et al.
Publicado: (2012)

The anti-oncogenic effect of 17-DMAG via the inactivation of HSP90 and MET pathway in osteosarcoma cells
por: KAWANO, MASANORI, et al.
Publicado: (2023)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells
por: Shu, Wenying, et al.
Publicado: (2023)

17-DMAG, an HSP90 Inhibitor, Ameliorates Multiple Organ Dysfunction Syndrome via Induction of HSP70 in Endotoxemic Rats
por: Wang, Yi-Li, et al.
Publicado: (2016)

Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
por: Sherrill, Beth, et al.
Publicado: (2010)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
por: Eustace, Alex J, et al.
Publicado: (2018)

Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2013)

P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
por: Kim, Hee Joung, et al.
Publicado: (2015)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

Development of the Rat Model of Lapatinib-Induced Diarrhoea
por: Bowen, Joanne M.
Publicado: (2014)

Lapatinib-induced acute generalized exanthematous pustulosis
por: Lakshmi, Chembolli, et al.
Publicado: (2010)

The concomitant use of lapatinib and paracetamol - the risk of interaction
por: Karbownik, Agnieszka, et al.
Publicado: (2018)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sn5tu0gut45d3i7mme3ehclp21